The Lancet Oncology
Издатель: Elsevier · ISSN 1470-2045 · 93 статей
- Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records
- Blank spaces on the map: genomics for global cancer research
- England's National Cancer Plan; ambition without accountability
- Re-evaluating aglatimagene in localised prostate cancer
- Re-evaluating aglatimagene in localised prostate cancer – Authors' reply
- Proton pump inhibitors and durvalumab in PACIFIC
- Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply
- Pelvic nodal SBRT: from feasibility to therapeutic value
- Organ-preserving multimodal therapy for patients with high-risk upper tract urothelial carcinoma in China (DISTINCT-I): a single-arm, phase 2 trial
- Prostate and pelvic nodal stereotactic body radiotherapy (SBRT) versus prostate-only SBRT for high-risk, localised prostate cancer (PACE-NODES): early adverse event results from an international, open-label, phase 3, randomised controlled trial
- PAHO region-wide access agreements for HPV
- ACS updates prostate cancer screening guidelines
- Trump cuts childhood vaccine recommendations
- Nigeria plans major expansion of radiotherapy capacity
- Delays in cancer referrals and care lead to harm and missed diagnoses in England
- Increased tobacco production and cigarette imports in Africa
- 2026 World Conference on Lung Cancer
- Kenya agrees major cuts to cancer drug prices
- Toxic dust around the World Trade Center
- Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis
- Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial
- Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial
- Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial
- An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial
- Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era
- Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study
- Burden of cancer in Africa, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023
- Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission
- Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population